Diurnal variation in cholesterol 7 alpha-hydroxylase activity is determined by the-203A > C polymorphism of the CYP7A1 gene

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00060000" target="_blank" >RIV/00023001:_____/16:00060000 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/16:10324350

Výsledek na webu

<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856193/pdf/CroatMedJ_57_0111.pdf" target="_blank" >https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856193/pdf/CroatMedJ_57_0111.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3325/cmj.2016.57.111" target="_blank" >10.3325/cmj.2016.57.111</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Diurnal variation in cholesterol 7 alpha-hydroxylase activity is determined by the-203A > C polymorphism of the CYP7A1 gene

Popis výsledku v původním jazyce

Aim To determine whether the promoter polymorphism -203A>C of cholesterol-7 alpha-hydroxylase encoding gene (CYP7A1) affects diurnal variation in CYP7A1 enzyme activity. Methods The study included 16 healthy male volunteers -8 homozygous for -203A and 8 homozygous for the -203C allele of CYP7A1. Three 15-hour examinations (from 7am to 10pm) were carried out for each of the participants: after one-day treatment with cholestyramine; after one-day treatment with chenodeoxycholic acid (CDCA); and a control examination without any treatment. The plasma concentration of 7 alpha-hydroxy-4-cholesten-3-one (C4), a marker of CYP7A1 activity, was determined in all the experiments at 90-min intervals. Results CYP7A1 activity was up-regulated after treatment with cholestyramine and suppressed after treatment with CDCA. There were no differences between -203A and -203C allele carriers in the response of enzyme activity to both drugs. In the control experiment, -203A allele carriers displayed diurnal variation in enzyme activity, whereas CYP7A1 activity did not change in -203C allele carriers. These results were confirmed by modeling the dynamics of C4 using polynomial regression. Conclusion The promoter polymorphism of the CYP7A1 gene has a pronounced impact on diurnal variation in CYP7A1 activity.

Název v anglickém jazyce

Diurnal variation in cholesterol 7 alpha-hydroxylase activity is determined by the-203A > C polymorphism of the CYP7A1 gene

Popis výsledku anglicky

Aim To determine whether the promoter polymorphism -203A>C of cholesterol-7 alpha-hydroxylase encoding gene (CYP7A1) affects diurnal variation in CYP7A1 enzyme activity. Methods The study included 16 healthy male volunteers -8 homozygous for -203A and 8 homozygous for the -203C allele of CYP7A1. Three 15-hour examinations (from 7am to 10pm) were carried out for each of the participants: after one-day treatment with cholestyramine; after one-day treatment with chenodeoxycholic acid (CDCA); and a control examination without any treatment. The plasma concentration of 7 alpha-hydroxy-4-cholesten-3-one (C4), a marker of CYP7A1 activity, was determined in all the experiments at 90-min intervals. Results CYP7A1 activity was up-regulated after treatment with cholestyramine and suppressed after treatment with CDCA. There were no differences between -203A and -203C allele carriers in the response of enzyme activity to both drugs. In the control experiment, -203A allele carriers displayed diurnal variation in enzyme activity, whereas CYP7A1 activity did not change in -203C allele carriers. These results were confirmed by modeling the dynamics of C4 using polynomial regression. Conclusion The promoter polymorphism of the CYP7A1 gene has a pronounced impact on diurnal variation in CYP7A1 activity.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FB - Endokrinologie, diabetologie, metabolismus, výživa

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13151" target="_blank" >NT13151: Polymorfismus cholesterol-7alfa-hydroxylasy jako prediktor odpovídavosti cholesterolémie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Croatian medical journal

ISSN

0353-9504

e-ISSN

—

Svazek periodika

57

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

HR - Chorvatská republika

Počet stran výsledku

7

Strana od-do

111-117

Kód UT WoS článku

000377053400004

EID výsledku v databázi Scopus

—